Clinical trials: Psoriatic-arthritis
Psoriasis, Arthritis, Psoriatic
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.
- Trial name
- NCT00161655
- Testing
- Etanercept, Methotrexate
- Where
- 8 sites in Denmark, Finland and 2 more
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriatic Arthritis
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
- Trial name
- NCT01925768
- Testing
- Apremilast 30 mg
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 219 people
- Sponsor
- Amgen
Psoriasis
Prevalence of Sonographic Abnormalities of Joints and Entheses in Psoriasis Patients With or Without Musculoskeletal Complains
The objectives of this study are: to estimate the prevalence and severity of inflammatory (synovitis, tenosynovitis, enthesitis, dactylitis) and structural (erosions, osteophytes, enthesophytes, cortical irregularities )…
- Trial name
- EchoPso (NCT04074070)
- Testing
- Ultrasound examination
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriatic Arthritis
Treatment With Apremilast in Patients With Psoriatic Arthritis
Apremilast (Otezla®) is a Federal Drug Administration (FDA)-approved treatment for psoriatic arthritis and psoriasis. Although there are a lot of data demonstrating how apremilast works in the laboratory, there are very few…
- Trial name
- NCT02558361
- Testing
- Treatment with Apremilast
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of South Florida
Psoriasis Vulgaris, Psoriatic Arthritis
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
This was a multicenter, centrally registered observational study without a control group. This observational study was a specified drug use-results survey conducted under GPSP to collect information on safety and efficacy during…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular Psoriasis
- Trial name
- NCT05215561
- Testing
- Cosentyx
- Where
- 21 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris, Psoriatic Arthritis
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
The main objective of this study is to investigate the safety and tolerability of si-544. Other objectives are to study the metabolism of si-544 in the body and to assess the effects of si-544 on cells of the body's immune system…
- Trial name
- NCT06191042
- Testing
- si-544
- Where
- 4 sites in Germany
- Volunteers
- 45 people
- Sponsor
- selectION Therapeutics GmbH
Psoriatic Arthritis
to Translate and Validate the TOPAS TORONTO PSORIATIC SCREENING QUESTIONNAIRE)Into Spanish
TO TRANSALETE AND VALIDATE DE TORONTO PSORIATIC ARTHRITIS SECREENING QUESTIONAIRE INTO SPANISH
- Trial name
- spanishTopas (NCT01891903)
- Where
- Colombia
- Volunteers
- 60 people
- Sponsor
- Reumatologia Integral LTDA
Psoriatic Arthritis
Metformin in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a systemic, inflammatory disease. The chronic inflammation in PsA predisposes patients to the metabolic syndrome (MetS). MetS is associated with systemic inflammation and proinflammatory cytokines.
- Trial name
- NCT02188654
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- University of Alexandria
Psoriasis
Swiss Dermatology Network of Targeted Therapies (SDNTT)
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept…
- Trial name
- SDNTT (NCT01706692)
- Testing
- Adalimumab, Etanercept, Infliximab
- Where
- 6 sites in Switzerland
- Volunteers
- 1,121 people
- Sponsor
- Swiss Dermatology Network for Targeted Therapies
Inflammatory Disorder of Immune System, Spondylitis, Ankylosing
Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases
Cannabis, in addition to its psychotropic properties, could have anti-inflammatory and immunomodulatory effects. Phytocannabinoids (pCBs) are a group of molecules naturally secreted by the cannabis plant.
- Conditions
- Inflammatory Disorder of Immune System, Spondylitis, Ankylosing, Arthritis, Rheumatoid, Arthritis, Psoriatic
- Trial name
- pCB-IMIDs (NCT06842316)
- Testing
- 1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Rheumatoid Arthritis, Psoriatic Arthritis
GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden
GÖTHA- The early arthritis and psoriasis study of Region Västra Götaland, Sweden - is a longitudinal observational study, which will prospectively and in parallel follow patients with newly diagnosed rheumatoid arthritis (RA…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Arthritis, Psoriasis
- Trial name
- GOTHA (NCT04190758)
- Testing
- Care as usual
- Where
- Sweden
- Volunteers
- 5,100 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Psoriatic Arthritis
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other…
- Trial name
- STEREO (NCT00235885)
- Testing
- adalimumab
- Where
- United States
- Volunteers
- 445 people
- Sponsor
- Abbott
Arthritis, Psoriatic
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
The aim of this study is to evaluate if the data obtained in controlled clinical trials are confirmed when Enbrel is used in usual clinical practice in Belgium according to local reimbursement criteria.
- Trial name
- PROVE (NCT00938015)
- Testing
- Questionnaire
- Where
- Belgium
- Volunteers
- 303 people
- Sponsor
- Pfizer
Psoriatic Arthritis
A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis
The purpose of this study is to evaluate treatment retention in psoriatic arthritis participants with STELARA or tumor necrosis factor alpha inhibitor (TNFi) therapies in relation to effectiveness, safety, benefit/risk and to…
- Trial name
- PsaBio (NCT02627768)
- Testing
- No Intervention
- Where
- 66 sites in Belgium, France and 5 more
- Volunteers
- 991 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Arthritic Psoriasis, Psoriasis (PsO)
Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study.
In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Parameters such as the thickness of the choroid layer, which plays a crucial role in maintaining normal eye…
- Conditions
- Arthritic Psoriasis, Psoriasis (PsO), Retinal Vessels
- Trial name
- PsA-RETINA (NCT07858591)
- Testing
- OCTA-SCP, OCTA-DCP, OCTA-RPC
- Where
- Turkey (Türkiye)
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Arthritis, Psoriatic
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha…
- Trial name
- AFFINITY (NCT05071664)
- Testing
- Guselkumab, Golimumab
- Where
- 82 sites in United States, Denmark and 8 more
- Volunteers
- 91 people
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis, Rheumatoid Arthritis
Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System
This study is a multicenter, prospective, non-randomized, non-controlled post-market clinical follow-up study. The primary objective of this study is to confirm the safety and performance of the A.L.P.S.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis
- Trial name
- NCT03626038
- Testing
- A.L.P.S. Proximal Humerus Plating System
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 135 people
- Sponsor
- Zimmer Biomet
Psoriatic Arthritis, Psoriasis
Assessment of Fatigue in Psoriatic Arthritis and Cutaneous Psoriasis Patients
Psoriatic arthritis is characterized with pain, swelling and joint stiffness. These are inflammatory reactions against tendons, ligaments and joints associated with fatigue.
- Trial name
- RPso-Fatigue (NCT06101706)
- Testing
- Fatigue assessment, Quality of life assessment, Assess severity of psoriatic arthritis
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Centre Hospitalier Henri Duffaut - Avignon
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of SPY072 in Rheumatic Disease
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
- Trial name
- SKYWAY-RD (NCT07148414)
- Testing
- SPY002-072
- Where
- 64 sites in United States, Bulgaria and 6 more
- Volunteers
- 285 people
- Sponsor
- Spyre Therapeutics, Inc.
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with…
- Trial name
- BE UNIQUE (NCT06506916)
- Testing
- bimekizumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL